Johnson & Johnson Stock Jumps 3% as Healthcare Rotation Lifts Shares
This article first appeared on GuruFocus. Johnson & Johnson (NYSE:JNJ), the healthcare heavyweight behind blockbuster medicines and medical…
Johnson & Johnson vs Abbott Laboratories: Which Healthcare Giant Offers the More Compelling Growth Story After Earnings?
Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7%…
We’re lifting our price target on Cardinal Health after issuing rosy profit guidance
Cardinal Health on Tuesday showed why the healthcare distributor belongs in our portfolio, delivering robust full-year earnings guidance…
Johnson & Johnson baby powder lawsuit: J&J offers $5.5 billion to settle 76,000 cancer claims
Johnson & Johnson (J&J) has agreed to pay an estimated $5.5 billion to settle tens of thousands of…
How a 44-Year-Old Could Build a $9,000 Monthly Paycheck by 60 Without Maxing a 401(k)
Quick Read Generating $108,000 annually from dividends requires roughly $2.7M at a 4% yield, $1.8M at 6%, or…
Johnson & Johnson (JNJ) Raised Its Outlook. Is It the Better Healthcare Stock to Own After Earnings?
Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7%…
Johnson & Johnson vs Abbott Laboratories: Two Healthcare Giants on Opposite Trajectories
Quick Read JNJ’s 64-year dividend streak and oncology momentum make it the steadier buy, while ABT’s 18x forward…
Market for psychedelic drugs to treat mental health gets a buy signal
Psilocybin mushrooms stand ready for harvest in a humidified “fruiting chamber.” John Moore | Getty Images Thursday’s announcement…
We’re trimming a stock into strength, raising our price target
We are selling 50 shares of Cardinal Health at roughly $235. Following the trade, Jim Cramer’s Charitable Trust…
Johnson & Johnson CEO: America’s innovation advantage starts with health
Johnson & Johnson CEO: America’s innovation advantage starts with health | Fortune Joaquin Duato is Chairman and Chief…
J&J starts head-to-head PFA trial against Boston Scientific device
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free…
Eli Lilly to acquire cancer drug maker Kelonia in deal worth up to $7B
Eli Lilly will acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion, the company…